Urinary concentrations of ADAM 12 from breast cancer patients pre- and post-surgery vs. cancer-free controls: a clinical study for biomarker validationReport as inadecuate

Urinary concentrations of ADAM 12 from breast cancer patients pre- and post-surgery vs. cancer-free controls: a clinical study for biomarker validation - Download this document for free, or read online. Document in PDF available to download.

Journal of Negative Results in BioMedicine

, 13:5

First Online: 01 April 2014Received: 20 December 2013Accepted: 18 March 2014DOI: 10.1186-1477-5751-13-5

Cite this article as: Nyren-Erickson, E.K., Bouton, M., Raval, M. et al. J Negat Results BioMed 2014 13: 5. doi:10.1186-1477-5751-13-5


BackgroundThe ADAMs A Disintegrin and Metalloproteinases are a family of multi-domain, zinc-dependent metalloproteinase enzymes. ADAM 12 has been previously associated with the onset and progression of breast cancer, and elevated levels of ADAM 12 have been previously found in the urine of breast cancer patients. Aims of the current study are: 1 establish the viability of urinary ADAM 12 as a diagnostic marker for breast cancer, and 2 explore the effects of surgical tumor removal on the levels of urinary ADAM 12.

MethodsA total of 96 patients have been recruited for this study, including 50 patients diagnosed with cancer, and 46 age-matched controls. Commercially available ELISA kits for ADAM 12 were used to quantify the presence and concentration of this enzyme in the urine from cancer patients with ductal carcinoma in situ DCIS and invasive breast cancer IBC both prior to any treatment and approximately two weeks following surgery, as well as from controls.

ResultsWe find no statistically significant differences between the concentrations of ADAM 12 in the urine of breast cancer patients prior to treatment and that of their age-matched controls; however the concentration of ADAM 12, both alone and as a function of urine total protein, are significantly elevated following surgery p < 0.0001. Patients who underwent a mastectomy have significantly higher urinary ADAM 12 concentrations than those who underwent a lumpectomy significant at p = 0.0271.

ConclusionsThese findings suggest that urinary ADAM 12 may not correlate directly with the status and stage of breast cancer as previously thought; rather these increases may be a result of tissue injury and inflammation from biopsy and surgical resection. Results of this study may suggest a need for biomarkers to be evaluated carefully in the context of tissue damage.

KeywordsA Disintegrin and Metalloproteinase ADAM12 ADAM12-S Breast cancer Cancer biomarker AbbreviationsADAM12A disintegrin and metalloproteinase isoform 12

DCISDuctal carcinoma in situ

IBCInvasive breast cancer

ELISAEnzyme-linked immunosorbent assay.

Electronic supplementary materialThe online version of this article doi:10.1186-1477-5751-13-5 contains supplementary material, which is available to authorized users.

Download fulltext PDF

Author: Erin K Nyren-Erickson - Michael Bouton - Mihir Raval - Jessica Totzauer - Sanku Mallik - Neville Alberto

Source: https://link.springer.com/

Related documents